Asghar Haider1, Simon R Bababeygy, Stephanie Y Lu. 1. *University of California, Irvine School of Medicine, Irvine, California; and †Department of Ophthalmology, Gavin Herbert Eye Institute, Irvine, California.
Abstract
PURPOSE: To report the first known case of retinal pigment epithelium hyperpigmentation changes and cystoid macular edema in a patient on nab-paclitaxel therapy. METHODS: Observational case report. RESULTS: A 72-year-old man on nab-paclitaxel therapy for non-small cell lung carcinoma developed cystoid macular edema with minimal capillary leakage with subsequent retinal pigment epithelium hyperpigmentation after resolution of cystoid macular edema. CONCLUSION: Nab-paclitaxel therapy may be associated with the development of retinal pigment epithelium hyperpigmentation in the setting of resolved minimal capillary leakage cystoid macular edema.
PURPOSE: To report the first known case of retinal pigment epithelium hyperpigmentation changes and cystoid macular edema in a patient on nab-paclitaxel therapy. METHODS: Observational case report. RESULTS: A 72-year-old man on nab-paclitaxel therapy for non-small cell lung carcinoma developed cystoid macular edema with minimal capillary leakage with subsequent retinal pigment epithelium hyperpigmentation after resolution of cystoid macular edema. CONCLUSION:Nab-paclitaxel therapy may be associated with the development of retinal pigment epithelium hyperpigmentation in the setting of resolved minimal capillary leakage cystoid macular edema.